v3.26.3
Stockholders' Equity - Narrative (Detail) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Apr. 30, 2025
Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]          
Common stock, shares issued (in shares) 56,692,755   56,325,429    
Aggregate intrinsic value of stock options exercised $ 26,966 $ 4,300      
Weighted average grant date fair value of share-based awards granted (in dollars per share) $ 64.21 $ 72.94      
Total unrecognized compensation cost $ 68,600        
Unrecognized compensation cost, weighted average remaining requisite service period 2 years 8 months 15 days        
Avitide          
Stockholders Equity Note Disclosure [Line Items]          
Common stock, shares issued (in shares)       52,935  
FlexBiosys          
Stockholders Equity Note Disclosure [Line Items]          
Common stock, shares issued (in shares)       5,517  
2018 Plan          
Stockholders Equity Note Disclosure [Line Items]          
Common stock shares reserved for issuance (in shares)         2,778,000
Shares available for future grants (in shares) 928,992        
Restricted Stock Units and Performance Stock Units          
Stockholders Equity Note Disclosure [Line Items]          
Aggregate intrinsic value of restricted stock units vested $ 22,100 $ 20,800      
Weighted average grant date fair value of restricted stock units granted (in dollars per share) $ 128.63 $ 144.23